Literature DB >> 9797363

A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors.

M Nakahara1, K Isozaki, S Hirota, J Miyagawa, N Hase-Sawada, M Taniguchi, T Nishida, S Kanayama, Y Kitamura, Y Shinomura, Y Matsuzawa.   

Abstract

BACKGROUND & AIMS: The c-kit gene encodes a receptor tyrosine kinase (KIT). Recently, we found gain-of-function mutations of the c-kit gene in gastrointestinal stromal tumors (GISTs). All mutations were confined within the 11 amino acids (Lys-550 to Val-560) in the juxtamembrane domain, but one GIST showed a novel deletion-type mutation at codon 579 (Asp) in the juxtamembrane domain. The aim of this study was to clarify whether the mutation is activating.
METHODS: Mutant c-kit cDNA was transfected into an interleukin 3 (IL-3)-dependent Ba/F3 murine lymphoid cell line, and the magnitude of autophosphorylation of the mutant KIT was examined with or without stem cell factor (SCF), a ligand of KIT. An in vitro kinase assay was also performed. The biological behavior of the transfectant was estimated by both an in vitro proliferation assay and in vivo transplantation to nude mice.
RESULTS: The mutant KIT exhibited constitutive phosphorylation and strong kinase activity without SCF. The transfectant grew autonomously without IL-3 and SCF, and it formed tumors in nude mice.
CONCLUSIONS: Deletion at codon 579 (Asp) in the juxtamembrane domain of the c-kit gene is a novel gain-of-function mutation other than the region between Lys-550 and Val-560.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797363     DOI: 10.1016/s0016-5085(98)70079-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  47 in total

Review 1.  Myofibroblasts: paracrine cells important in health and disease.

Authors:  D W Powell
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

2.  TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.

Authors:  B Lawrence; A Perez-Atayde; M K Hibbard; B P Rubin; P Dal Cin; J L Pinkus; G S Pinkus; S Xiao; E S Yi; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.

Authors:  Justin M Drake; Nicholas A Graham; Tanya Stoyanova; Amir Sedghi; Andrew S Goldstein; Houjian Cai; Daniel A Smith; Hong Zhang; Evangelia Komisopoulou; Jiaoti Huang; Thomas G Graeber; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

4.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

Authors:  M L Lux; B P Rubin; T L Biase; C J Chen; T Maclure; G Demetri; S Xiao; S Singer; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 5.  Tailored management of primary gastrointestinal stromal tumors.

Authors:  Mark S Etherington; Ronald P DeMatteo
Journal:  Cancer       Date:  2019-04-01       Impact factor: 6.860

6.  Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI.

Authors:  Tanya M Laidlaw; John W Steinke; Adrienne M Tiñana; Chunli Feng; Wei Xing; Bing K Lam; Sailaja Paruchuri; Joshua A Boyce; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2011-02-01       Impact factor: 10.793

Review 7.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

Review 8.  Physiology, injury, and recovery of interstitial cells of Cajal: basic and clinical science.

Authors:  Jan D Huizinga; Natalia Zarate; Gianrico Farrugia
Journal:  Gastroenterology       Date:  2009-09-22       Impact factor: 22.682

9.  Neurofibromatosis with gastrointestinal stromal tumors: insights into the association.

Authors:  Shih-Ping Cheng; Ming-Jer Huang; Tsen-Long Yang; Chin-Yuan Tzen; Chien-Liang Liu; Tsang-Pai Liu; Shu-Ching Hsiao
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

Review 10.  Targeted Therapies in the Treatment of Sarcomas.

Authors:  Brianna Hoffner; Anthony D Elias; Victor M Villalobos
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.